Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Filings indexed 626 across all filing types
Latest filing 2023-08-09 Earnings Release
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook
Earnings Release Classification · 100% confidence The document is a detailed announcement titled "QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook." It contains key financial metrics (Net sales, EPS, Operating income) for Q2 2023 and H1 2023, compares them to prior periods, provides management commentary, and includes detailed tables breaking down sales by product type and geography. This structure is characteristic of an initial announcement of periodic financial results, which is defined as an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR), as it focuses on highlights and outlook updates rather than the full statutory filing. Q2 2023
2023-08-09 English
SD
Regulatory Filings
2023-05-26 English
Q1 statement / Q1 financial report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the U.S. Securities and Exchange Commission by QIAGEN N.V. It explicitly contains the 'U.S. GAAP Quarterly Report for the Period Ended March 31, 2023' as Exhibit 99.1, which includes comprehensive condensed consolidated financial statements (balance sheets, income statements, cash flows) and notes. Since it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2023
2023-05-05 English
6-K
Regulatory Filings
2023-05-04 English
6-K
Regulatory Filings
2023-05-04 English
IRANNOTICE
Regulatory Filings
2023-05-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.